Researchers discovered that ALPK2, a heart-specific enzyme, may protect against HFpEF by activating TPM1 in heart muscle ...

Currently, there are only two drugs for HFpEF: SGLT2 inhibitor and ARNI. The ALPK2/TPM1 regulatory axis may provide a unique therapeutic target for HFpEF, allowing the development of new treatment ...

We used a unique 3D microfluidic model of tumors to investigate the mechanisms of treatment resistance to CAR-T cells that were designed to target B7 ... While there are several different 3D ...